Facebook Instagram Twitter Linkedin Youtube Podcast

Duchenne News Tags: Wave Life Sciences

Search
Tags
Tags
Antisense Therapeutics Astellas Pharma Avidity Biosciences Catalyst Pharmaceuticals Dyne Therapeutics Edgewise Therapeutics Entrada Therapeutics FibroGen Italfarmaco NS Pharma PepGen Pliant Therapeutics PTC Therapeutics REGENXBIO Santhera Sarepta Therapeutics Solid Biosciences Wave Life Sciences
April 5, 2023

Wave Life Sciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Wave Life Sciences announces financial results for the fourth quarter and full year ended December 31, 2022 and provided a business update.
Read More
December 20, 2022

Wave Life Sciences Announces Positive Update from Phase 1b/2a Study of WVE-N531 in Duchenne

Wave Life Sciences announces positive update from Phase 1b/2a study of WVE-N531 in Duchenne
Read More

Jett Foundation, Inc.
65 Cordage Park Circle
Suite 130 | Plymouth, MA 02360
781-585-5566 | info@jettfoundation.org

Gold Transparency 2022 Candid. Logo
Sitemap
© 2023 All rights reserved. Powered by Getfused

Support Jett Foundation

Donate Today
Jett Foundation, Inc. is a 501(c)3 registered tax-exempt nonprofit organization. Our Federal Tax ID is 04-3563445.

Stay Connected With Us

Sign up to receive our newsletter and updates.
Required fields are denoted with an asterisk (*)





    This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

    Accessible Vehicle Fund Applications Open

    Apply Today